Editorial
doi: 10.1111/apt.17449.
Editorial: clinical outcomes in lean NAFLD-the devil is in the details
Affiliations
- PMID: 37053487
- DOI: 10.1111/apt.17449
Item in Clipboard
Editorial
Editorial: clinical outcomes in lean NAFLD-the devil is in the details
Aliment Pharmacol Ther.
2023 May.
No abstract available
Comment in
-
Editorial: clinical outcomes in lean NAFLD - the devil is in the details. Authors' reply.Aliment Pharmacol Ther. 2023 May;57(9):1042-1043. doi: 10.1111/apt.17453. Aliment Pharmacol Ther. 2023. PMID: 37053482 Free PMC article. No abstract available.
Comment on
-
Higher mortality among lean patients with non-alcoholic fatty liver disease despite fewer metabolic comorbidities.Aliment Pharmacol Ther. 2023 May;57(9):1014-1027. doi: 10.1111/apt.17424. Epub 2023 Feb 23. Aliment Pharmacol Ther. 2023. PMID: 36815445 Free PMC article.
Similar articles
-
Editorial: clinical outcomes in lean NAFLD - the devil is in the details. Authors' reply.Aliment Pharmacol Ther. 2023 May;57(9):1042-1043. doi: 10.1111/apt.17453. Aliment Pharmacol Ther. 2023. PMID: 37053482 Free PMC article. No abstract available.
-
Lean non-alcoholic fatty liver disease (lean NAFLD): characteristics, metabolic outcomes and risk factors from a 7-year prospective, community cohort study from Sri Lanka.Hepatol Int. 2019 May;13(3):314-322. doi: 10.1007/s12072-018-9916-4. Epub 2018 Dec 11. Hepatol Int. 2019. PMID: 30539516
-
Nonalcoholic fatty liver disease in lean subjects: Prognosis, outcomes and management.World J Gastroenterol. 2020 Nov 14;26(42):6514-6528. doi: 10.3748/wjg.v26.i42.6514. World J Gastroenterol. 2020. PMID: 33268944 Free PMC article.
-
Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol. 2020 Aug;5(8):739-752. doi: 10.1016/S2468-1253(20)30077-7. Epub 2020 May 12. Lancet Gastroenterol Hepatol. 2020. PMID: 32413340
-
Lean non-alcoholic fatty liver disease.Clin Nutr. 2019 Jun;38(3):975-981. doi: 10.1016/j.clnu.2018.08.008. Epub 2018 Aug 17. Clin Nutr. 2019. PMID: 30466956 Review.
Cited by
-
Genetic and epigenetic determinants of non-alcoholic fatty liver disease (NAFLD) in lean individuals: a systematic review.Transl Gastroenterol Hepatol. 2023 Dec 6;9:11. doi: 10.21037/tgh-23-31. eCollection 2024. Transl Gastroenterol Hepatol. 2023. PMID: 38317742 Free PMC article. Review.
-
Editorial: clinical outcomes in lean NAFLD - the devil is in the details. Authors' reply.Aliment Pharmacol Ther. 2023 May;57(9):1042-1043. doi: 10.1111/apt.17453. Aliment Pharmacol Ther. 2023. PMID: 37053482 Free PMC article. No abstract available.
References
REFERENCES
-
- Teng ML, Ng CH, Huang DQ, Chan KE, Tan DJ, Lim WH, et al. Global incidence and prevalence of non-alcoholic fatty liver disease. Clin Mol Hepatol. 2023;29(Suppl):S32-42. https://doi.org/10.3350/cmh.2022.0365
-
- Powell EE, Wong VW-S, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397:2212-24.
-
- Huang DQ, Downes M, Evans RM, Witztum JL, Glass CK, Loomba R. Shared mechanisms between cardiovascular disease and NAFLD. Semin Liver Dis. 2022;42:455-64.
-
- Tan DJH, Setiawan VW, Ng CH, Lim WH, Muthiah MD, Tan EX, et al. Global burden of liver cancer in males and females: changing etiological basis and the growing contribution of NASH. Hepatology. 2023;57:77(4):1150-63. https://doi.org/10.1002/hep.32758
-
- Ye Q, Zou B, Yeo YH, Li J, Huang DQ, Wu Y, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:739-52.
Publication types
MeSH terms
LinkOut - more resources
Medical